Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity
Not all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-09-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2021.1975228 |
| _version_ | 1819071369255583744 |
|---|---|
| author | Agustinus Darmadi Hariyanto Tiara Bunga Mayang Permata Soehartati Argadikoesoema Gondhowiardjo |
| author_facet | Agustinus Darmadi Hariyanto Tiara Bunga Mayang Permata Soehartati Argadikoesoema Gondhowiardjo |
| author_sort | Agustinus Darmadi Hariyanto |
| collection | DOAJ |
| description | Not all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseases, minimalize chronic inflammatory diseases by enlisting various immunoregulatory mechanisms. The balance between effector T cells (Teff) and regulator T cells is crucial in determining the outcome of an immune response. Regarding tumors, activation or expansion of TReg cells reduces anti-tumor immunity. TReg cells inhibit the activation of CD4+ and CD8+ T cells and suppress anti-tumor activity in the tumor microenvironment. In addition, TReg cells also promote tumor angiogenesis both directly and indirectly to ensure oxygen and nutrient transport to the tumor. There is accumulating evidence showing a positive result that removing or suppressing TReg cells increases anti-tumor immune response. However, depletion of TReg cells will cause autoimmunity. One strategy to improve or restore tumor immunity is targeted therapy on the dominant effector TReg cells in tumor tissue. Various molecules such as CTLA-4, CD4, CD25, GITR, PD-1, OX40, ICOS are in clinical trials to assess their role in attenuating TReg cells’ function. |
| first_indexed | 2024-12-21T17:20:44Z |
| format | Article |
| id | doaj.art-d55152cdce5a47e6b3b19359dad684a5 |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-12-21T17:20:44Z |
| publishDate | 2021-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-d55152cdce5a47e6b3b19359dad684a52022-12-21T18:56:11ZengTaylor & Francis GroupImmunological Medicine2578-58262021-09-010011410.1080/25785826.2021.19752281975228Role of CD4+CD25+FOXP3+ TReg cells on tumor immunityAgustinus Darmadi Hariyanto0Tiara Bunga Mayang Permata1Soehartati Argadikoesoema Gondhowiardjo2Faculty of Medicine, Department of Radiotherapy, Universitas Indonesia/Cipto Mangunkusumo National General HospitalFaculty of Medicine, Department of Radiotherapy, Universitas Indonesia/Cipto Mangunkusumo National General HospitalFaculty of Medicine, Department of Radiotherapy, Universitas Indonesia/Cipto Mangunkusumo National General HospitalNot all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseases, minimalize chronic inflammatory diseases by enlisting various immunoregulatory mechanisms. The balance between effector T cells (Teff) and regulator T cells is crucial in determining the outcome of an immune response. Regarding tumors, activation or expansion of TReg cells reduces anti-tumor immunity. TReg cells inhibit the activation of CD4+ and CD8+ T cells and suppress anti-tumor activity in the tumor microenvironment. In addition, TReg cells also promote tumor angiogenesis both directly and indirectly to ensure oxygen and nutrient transport to the tumor. There is accumulating evidence showing a positive result that removing or suppressing TReg cells increases anti-tumor immune response. However, depletion of TReg cells will cause autoimmunity. One strategy to improve or restore tumor immunity is targeted therapy on the dominant effector TReg cells in tumor tissue. Various molecules such as CTLA-4, CD4, CD25, GITR, PD-1, OX40, ICOS are in clinical trials to assess their role in attenuating TReg cells’ function.http://dx.doi.org/10.1080/25785826.2021.1975228tregregulatory t cellsanti-tumor immunityimmunotherapytreg-targeting therapy |
| spellingShingle | Agustinus Darmadi Hariyanto Tiara Bunga Mayang Permata Soehartati Argadikoesoema Gondhowiardjo Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity Immunological Medicine treg regulatory t cells anti-tumor immunity immunotherapy treg-targeting therapy |
| title | Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity |
| title_full | Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity |
| title_fullStr | Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity |
| title_full_unstemmed | Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity |
| title_short | Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity |
| title_sort | role of cd4 cd25 foxp3 treg cells on tumor immunity |
| topic | treg regulatory t cells anti-tumor immunity immunotherapy treg-targeting therapy |
| url | http://dx.doi.org/10.1080/25785826.2021.1975228 |
| work_keys_str_mv | AT agustinusdarmadihariyanto roleofcd4cd25foxp3tregcellsontumorimmunity AT tiarabungamayangpermata roleofcd4cd25foxp3tregcellsontumorimmunity AT soehartatiargadikoesoemagondhowiardjo roleofcd4cd25foxp3tregcellsontumorimmunity |